Company: IMCR
Filing Date: 2025-03-24
Form Type: PRE 14A
Source: 0001140361-25-010035
Chunk: 119

Company: Immunocore Holdings plc
Filing Date: 2025-03-24
Form: PRE 14A
Chunk 119
---
 63,699 |     |           — |     |        — |     |       63,699 |     |        — |     | —         |     |            — |     |       63,699 |
| Professor Sir Peter Ratcliffe |     |     58,699 |     |           — |     |        — |     |       58,699 |     |        — |     | —         |     |            — |     |       58,699 |
| Siddharth Kaul                |     |     61,199 |     |           — |     |        — |     |       61,199 |     |        — |     | —         |     |            — |     |       61,199 |
| Total director compensation   |     |  1,070,995 |     |      45,329 |     |   16,500 |     |    1,132,824 |     |  606,375 |     | —         |     |      606,375 |     |    1,739,199 |

A-17

TABLE OF CONTENTS

Notes to the compensation table:

| 1. | Dr. Jallal’s benefits comprise health cover, life insurance, disability cover and tax equalization gross-up payments paid with respect to the portion of her income subject to United Kingdom taxation. Dr. Herbst and Kristine Peterson’s benefits comprise tax equalization gross-up payments paid with respect to the portion of their income subject to United Kingdom taxation. |

| 2. | Represents a performance-based cash bonus awarded to Dr. Jallal in connection with the achievement of 2024 annual performance milestones (paid in 2025). Dr. Jallal was assigned a target bonus expressed as a percentage of her base salary, and the target bonus amount for Dr. Jallal for 2024 was 75% (2023: 75%). For 2024, the Board determined to award Dr. Jallal an annual bonus of $573,750 (2023: $606,375) (reflecting an achievement level of 100% (2023: 110%)), as reflected in the “Annual Bonus” column of the table above. |

| 3. | For awards granted in the years ended 31 December 2024 and 2023, the exercise price is equal to the market value of the shares on the date of the grant and